Prognostic Impact of del(17p) and del(22q) as Assessed by Interphase FISH in Sporadic Colorectal Carcinomas

María González-González1, Luis Muñoz-Bellvis2, Carlos Mackintosh3, Celia Fontanillo4, M. Laura Gutiérrez1, M. Mar Abad5, Oscar Bengoechea5, Cristina Teodosio1, Emilio Fonseca6, Manuel Fuentes1, Javier De Las Rivas4, Alberto Orfao1*, José María Sayagués1*

1 Servicio General de Citometría, Departamento de Medicina and Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Hospital Universitario de Salamanca-IIBSAL, Universidad de Salamanca, Salamanca, Spain, 2 Unidad de Cirugía Hepatobiliopancreática, Departamento de Cirugía, Hospital Universitario de Salamanca-IIBSAL, Salamanca, Spain, 3 Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Universidad de Salamanca, Salamanca, Spain, 4 Grupo de Investigación en Bioinformática y Genómica Funcional, Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Universidad de Salamanca, Salamanca, Spain, 5 Departamento de Patología, Hospital Universitario de Salamanca-IIBSAL, Salamanca, Spain, 6 Departamento de Oncología Médica, Hospital Universitario de Salamanca-IIBSAL, Salamanca, Spain

Abstract

Background: Most sporadic colorectal cancer (sCRC) deaths are caused by metastatic dissemination of the primary tumor. New advances in genetic profiling of sCRC suggest that the primary tumor may contain a cell population with metastatic potential. Here we compare the cytogenetic profile of primary tumors from liver metastatic versus non-metastatic sCRC.

Methodology/Principal Findings: We prospectively analyzed the frequency of numerical/structural abnormalities of chromosomes 1, 7, 8, 13, 14, 17, 18, 20, and 22 by iFISH in 58 sCRC patients: thirty-one non-metastatic (54%) vs. 27 metastatic (46%) disease. From a total of 18 probes, significant differences emerged only for the 17p11.2 and 22q11.2 chromosomal regions. Patients with liver metastatic sCRC showed an increased frequency of del(17p11.2) (10% vs. 67%; p < .001) and del(22q11.2) (0% vs. 22%; p = .02) versus non-metastatic cases. Multivariate analysis of prognostic factors for overall survival (OS) showed that the only clinical and cytogenetic parameters that had an independent adverse impact on patient outcome were the presence of del(17p) with a 17p11.2 breakpoint and del(22q11.2). Based on these two cytogenetic variables, patients were classified into three groups: low- (no adverse features), intermediate- (one adverse feature) and high-risk (two adverse features)- with significantly different OS rates at 5-years (p < .001): 92%, 53% and 0%, respectively.

Conclusions/Significance: Our results unravel the potential implication of del(17p11.2) in sCRC patients with liver metastasis as this cytogenetic alteration appears to be intrinsically related to an increased metastatic potential and a poor outcome, providing additional prognostic information to that associated with other cytogenetic alterations such as del(22q11.2). Additional prospective studies in larger series of patients would be required to confirm the clinical utility of the new prognostic markers identified.

Introduction

Metastatic dissemination of the primary tumor is the major cause of death of sporadic colorectal cancer (sCRC) patients [1]. Metastasis is a complex multi-step process which is driven by sequential accumulation of multiple genetic and molecular alterations and/or epigenetic changes involving one or multiple tumor cell clones. In recent years, data accumulated about the intratumoral pathways of clonal evolution of sCRC associated with chromosomal alterations/instability, indicates that liver metastatic lesions may derive from descendants of a tumor cell clone which is already present in the primary tumor [2]. Advances in genetic profiling of cancer also suggest that the metastatic potential of human tumors is encoded in the bulk of a primary tumor, as metastatic tumors systematically contain those genetic abnormalities observed in the primary tumor sample from the same subject. However, the precise molecular changes associated with the development of sCRC with liver metastasis still remain to be identified [2]. Multiple recurrent chromosomal abnormalities that are found in primary tumours have been associated with
metastatic CRC, including gains of chromosomes 8q, 13q and 20q and losses of the 1p, 6p, 17p, 18q and 22q chromosomal regions [3–5].

In a recent study, we described a detailed map of the genetic abnormalities of primary tumors from sCRC patients with liver metastasis by high-resolution SNP arrays. In this study, we reported the existence of a highly prevalent breakpoint region in the great majority of primary sCRC patients who had synchronous liver metastasis. Such breakpoint region is located in the centromeric region of chromosome 17p, between the genome coordinates 20,156,497 bp and 22,975,771 bp [6]. This breakpoint region has been previously associated with i) a homogeneous genetic profile consisting of a higher frequency of abnormalities of chromosomes 1p, 7, 8, 13q, 17p, 18q, 20q and 22q and ii) an adverse clinical outcome [7]. However, delineation of the minimal common breakpoint region at chromosome 17p11.2 and its potential prognostic value in sCRC tumors, remain to be fully defined.

In the present study we investigated the prognostic value of structural/numerical abnormalities of the most frequently altered chromosomes in liver metastatic colorectal carcinomas from 58 sCRC patients (27 liver metastatic vs. 31 non-metastatic tumors) with a long median follow-up, as detected by interphase fluorescence in situ hybridization (iFISH). Overall, our results show that the occurrence of del(17p) involving the 17p11.2 breakpoint region is an independent prognostic factor for overall survival, as confirmed in a larger series of 119 patients from the GEO public database. However, we have demonstrated that the combined assessment of del(22q11) and del(17p11.2) increased the predictive value for a liver metastatic tumor.

Materials and Methods

Patients and samples
In the present study, we prospectively analyzed surgical specimens from 58 patients diagnosed with a sCRC between 1999 and 2010 (38 males and 20 females; median age of 69 years, ranging from 38 to 83 years) after informed consent was given by each subject. All patients underwent surgical resection of primary tumors at the Department of Surgery of the University Hospital of Salamanca (Salamanca, Spain) and they were diagnosed and classified according to the WHO criteria [8] prior to any treatment was given. Fourteen primary tumors were localized in the rectum and the other 44 were localized either in the right (caecum, ascending or transverse) or the left (descending and sigmoid) colon, with an overall mean size of 5.3±2 cm. According to tumor grade, 39 cases were classified as well-differentiated tumors, 15 as moderately- and four as poorly-differentiated carcinomas. In all cases, histopathological grade was confirmed in a second independent evaluation by an experienced pathologist. Median follow-up at the moment of closing this study was of 96 months (range: 12–124 months). The study was approved by the local ethics committee of the University Hospital of Salamanca (Salamanca, Spain) and informed consent was given by each individual, prior to entering the study.

From the 58 cases analyzed, 27 (47%) tumors had liver metastases (group 1; median follow-up of 37 months; pT3–4 pN1–2 M1) identified either at time of colorectal surgery (n = 16) or during the first year after initial diagnosis (n = 11); they all underwent complete surgical resection of both their primary and metastatic CRC. The other 31 (53%) patients corresponded to non-metastatic sCRC selected on the basis of a long follow-up in the absence of liver metastasis (median follow-up of 99 months; pT2–4 pN0 M0) to ensure their non-metastatic nature (group 2).

After histopathological diagnosis was established, part of the primary tumor was used to prepare single-cell suspensions. Once prepared, single cell suspensions were resuspended in methanol/acetic (3/1; vol/vol) and stored at −20°C for further iFISH analyses, as described elsewhere [2]. The remaining tissue was either fixed in formalin and embedded in paraffin, or frozen in liquid nitrogen and stored at room temperature (RT) and at −80°C, respectively. Each individual tissue sample was also evaluated after haematoxylin-eosin staining, to confirm the presence of tumor cells and to evaluate their quantity.

Interphase fluorescence in situ hybridization (iFISH) studies
Mixed single-cell suspensions from different samples obtained from each tumor were used for iFISH studies, after fixation in 3/1 methanol/acetic (vol/vol). A set of 18 different probes (Vysis Inc, Downers Grove, IL) specific for those chromosomes and chromosomal regions most frequently gained/amplified and deleted colorectal carcinomas with liver metastases [6], were systematically used in double and triple staining with the Spectrum Orange (SO), Spectrum Green (SG) and Spectrum Aqua (SA) fluorochromes: for chromosome 1, the LSI p58 (1p36) (SO)/TelEvisyon 1p (SG)/LSI 1q25 (SA) Multi-color probe was employed; for chromosome 7, the LSI D7S486 (7q31) (SO)/CEP 7 (SA) Dual Color probe was used; for chromosome 8, the LSI LPL (8p22) (SO)/CEP 8 (SA)/MYC (8q24) (SG) Multi-color probe was employed; for chromosome 13, the LSI RB1 13q14 (SO)/LSI 13q34 LAMP1 (SG) was used; for chromosome 14, the LSI IGH (14q32.33) Dual Color, Break Apart probe was selected; for chromosome 17, the LSI TP53 (17p13) (SO)/CEP 17 (SA) probe combination was employed; for chromosome 18, the LSI BCL2 (18q21) (SO)/CEP 18 (SA) probe combination was used; for chromosome 20, the LSI ZNF217 (20q13.2) (SO)/CEP 20 (SG) probe was employed; and, for chromosome 22, the LSI BCR (22q11.2) probe was used. We have previously found in primary tumors [6] and their paired liver metastases [9] a high prevalence of gains of chromosomes 7, 8q, 11q, 13q, 20q and X together with losses of the 1p, 8p, 17p and 18q chromosomal regions; in this series of cases, the breakpoints found at the centromeric region of chromosome 17p were variable and were mapped between the genomic coordinates 20,156,497 bp and 22,975,771 bp by SNP’s arrays. Herein, we investigated the presence of breakpoints at chromosome 17p11.2 using iFISH probes specifically designed and manufactured for this purpose (Kreatech Diagnostics, Amsterdam, The Netherlands), as schematically described in Figure 1.

The specific methods and procedures used for the iFISH studies have been previously described in detail [2] and for the investigation of the relationships existing between those genes coded at the 17p11.2, 17p13.1 and 22q11.2 chromosomal regions and other genes, the Ingenuity Pathway Analysis software (Ingenuity System®, www.ingenuity.com) was used.

External validation of the prognostic impact of del(17p) and del(22q)
External validation of the prognostic impact of del(17p) and del(22q) was performed in a previously reported group of sCRC patients from which aCGH files (MHP Human 1 Mb) and clinical data were publicly available at the GEO database (accession number GSE12520; genomic markers that predict survivorship in colorectal cancer) [10]. From all cases available in the dataset, we selected those studied with the MHP Human 1 Mb CGH array platform for a total of 109 cases: 81 sCRC from Edinburgh...
(Scotland, UK) and 38 from Hong Kong. Gpr files were preprocessed and normalized as described elsewhere [11]. Patients included in this external validation group were classified according to the Duke’s staging system as follows: stage A, 7.5% (n = 8), B, 44.9% (n = 48), C, 39.2% (n = 42) and stage D (metastatic), 8.5% (n = 9). Median of follow up of these patients was 67 months, with a median overall survival of 28.7 months (range: 0.3–147.2 months).

Statistical methods
For all continuous variables, mean values and their standard deviation (SD) and range were calculated using the SPSS software package (SPSS 15.0 Inc, Chicago, IL, USA); for dichotomic variables, frequencies were reported. In order to evaluate the statistical significance of differences observed between groups, the Student’s T and the Mann-Whitney U tests were used for continuous variables, depending on whether they displayed or not a normal distribution, respectively. For qualitative variables, the X² test was applied (cross-tab; SPSS). Overall survival (OS) curves were plotted according to the method of Kaplan and Meier, and the log-rank test (one-sided) was used to establish the statistical significance of the differences observed between survival curves (survival; SPSS). Multivariate analysis of prognostic factors for OS was performed using the Cox stepwise regression (forward selection) model (regression, SPSS). For multivariate analysis only those variables showing a significant association with OS in the univariate analysis were included. Statistical significance was considered to be present once P values (or, where appropriate, Pearson-corrected P values) were <.05.

Results
Clinical and biological characteristics of liver metastatic versus non-metastatic sporadic colorectal carcinoma (sCRC)
Overall, sCRC cases with liver metastases showed a higher frequency of lymph node metastases (p<.001) and abnormally increased CEA serum levels (p<.001) than non-metastatic patients (Table 1). From the prognostic point of view, sCRC with liver metastases also showed a higher frequency of deaths in association
with a significantly shortened patient overall survival (median of 25 months vs. not reached, respectively; p≤.001). By contrast, no significant differences were found between liver metastatic vs. non-metastatic CRC cases, regarding patient age, gender, tumor localization, histological grade and size, and alkaline phosphatase serum levels (Table 1).

Chromosomal alterations in metastatic vs non-metastatic sCRC

For most chromosomes analysed, sCRC with liver metastases showed similar cytogenetic profiles to those of non-metastatic tumors; this included similar (p>.05) frequencies of del(1p) (48% vs. 42%), polymyso of chromosome 7 (59% vs. 45%), del(8p) associated to gains of 8q (44% vs. 26%), polymysmy of chromosome 13 (74% vs. 58%), del(18q) (52% vs. 32%) and gain of chromosome 20 (63% vs. 39%) (Table 2). The only statistically significant differences found between liver metastatic and non-metastatic sCRC were those involving chromosomes 17p (p = .05) and 22q (p = .02): all cases showing del(22q) corresponded to liver metastatic tumors (0% vs. 22%); del(17p13) was found in 74% of liver metastatic vs. 19% of non-metastatic cases; del(17p13) with a breakpoint at 17p11.2 was almost exclusively detected among sCRC with liver metastases (67% vs. 10%, p<.001) (Table 2), and; all except one case with del(22q) (n = 5) also demonstrated del(17p11.2) while16 cases which had del(17p11.2) did not carry del(22q). The remaining 36 tumors carried none of the two chromosomal alterations. Interestingly, whenever these two chromosomal alterations were detected, either individually or in combination, they were present in all tumor cells, suggesting they had been acquired in the ancestral tumor cell clone.

Overall, a total of 36 genes are coded at the 17p11.2, 17p13.1 and 22q11.2 chromosomal regions (Table 3); 11 out of these 36 genes (31%) have been found to be involved in cancer. The network of functional interactions among these genes and other related downstream genes implicated in cancer is depicted in Figure 2. As shown in it, such cancer-associated genes deleted in sCRC cases with del(17p11.2) and del(22q11.2) directly related to several well-established biomarkers of sCRC such as the EGFR, BCL2, BAX and TP53 genes [12–15].

Impact of chromosomal alterations and other disease features of liver metastatic vs. non-metastatic sCRC on patient overall survival

Regarding prognosis, the presence of both del(17p13) (p = .04) -including del(17p11.2) (p<.001) - and del(22q11) (p<.001) were associated with a significantly inferior outcome. Other disease features that showed an adverse impact on patient OS were: increased (>7.5 ng/ml) CEA serum levels (p<.001), male gender (p = .04), lymph node involvement (p<.001) and, metastatic liver disease (p<.001) (Figure 3).

Multivariate analysis of the prognostic factors for OS showed that the most informative combination of independent variables to predict an adverse outcome was the presence of del(17p11.2) (p = .04) and del(22q11.2) (p = .002). Based on these two cytoge-

Table 1. Clinical and biological characteristics of liver metastatic (n = 27) versus non-metastatic (n = 31) sporadic colorectal carcinoma (sCRC) patients.

|                      | Liver metastatic sCRC (n = 27) | Non-metastatic sCRC (n = 31) | p-value | Total cases (n = 58) |
|----------------------|--------------------------------|-----------------------------|---------|----------------------|
| Age (years)*         | 73 (48–80)                     | 72 (38–83)                  | NS      | 72 (38–83)           |
| Gender               |                                |                             |         |                      |
| F                    | 11 (41%)                       | 9 (29%)                     | NS      | 20 (34%)             |
| M                    | 16 (59%)                       | 22 (71%)                    |         | 38 (66%)             |
| Tumor Localization   |                                |                             |         |                      |
| Rectum               | 5 (19%)                        | 11 (36%)                    |         | 16 (28%)             |
| Left colon           | 13 (48%)                       | 15 (48%)                    |         | 28 (52%)             |
| Right colon          | 9 (33%)                        | 5 (16%)                     |         | 14 (20%)             |
| Histological grade   |                                |                             |         |                      |
| Well-differentiated  | 16 (59%)                       | 23 (74%)                    |         | 39 (67%)             |
| Moderate-differentiated | 8 (30%)                      | 7 (22%)                     | NS      | 15 (26%)             |
| Poorly-differentiated | 3 (11%)                       | 1 (4%)                      |         | 4 (7%)               |
| Histopathology       |                                |                             |         |                      |
| pN0                  | 7 (26%)                        | 31 (100%)                   |         | 38 (66%)             |
| pN1                  | 12 (44%)                       | 0 (0%)                      | p≤.001  | 12 (21%)             |
| pN2                  | 8 (30%)                        | 0 (0%)                      |         | 8 (13%)              |
| Tumor Size (cm)*     | 5 (2.5–9)                      | 5 (2.5–14)                  | NS      | 5 (2.5–14)           |
| Serum ALP (mg/dl)    | 94 (1–330)                     | 108 (55–495)                | NS      | 101 (1–495)          |
| Serum CEA (ng/ml)    | 45.4 (0.8–4598)                | 3.2 (0.6–84)                | p≤.001  | 7.2 (0.6–4598)       |
| Deaths               | 20 (74%)                       | 3 (10%)                     | p≤.001  | 23 (40%)             |
| Median OS (months)*  | 25                             | Not Reached                 | p≤.001  | Not Reached          |

*Results expressed as median (range) or as number of cases (percentage); NS: statistically not significant (p>.05); F: female; M: male; ALP: alkaline phosphatase; CEA: Carcinoembryonic antigen; OS: overall survival.

doi:10.1371/journal.pone.0042683.t001
Table 2. Chromosomal alterations of primary tumors from liver metastatic (n = 27) versus non-metastatic sCRC patients (n = 31).

| Chromosomal Alteration | Liver metastatic tumors (n = 27) | Non-metastatic tumors (n = 31) | p-value | Total cases (n = 58) |
|------------------------|---------------------------------|-------------------------------|---------|---------------------|
| Chromosome 1           |                                 |                               |         |                     |
| Normal                 | 7 (26%)                         | 14 (45%)                      |         | 21 (36%)            |
| del(1p)                | 13 (48%)                        | 13 (42%)                      | NS      | 26 (45%)            |
| Polysomy               | 7 (26%)                         | 4 (13%)                       |         | 11 (19%)            |
| Chromosome 7           |                                 |                               |         |                     |
| Normal                 | 5 (19%)                         | 14 (45%)                      |         | 19 (33%)            |
| del(7q)                | 5 (19%)                         | 1 (3%)                        | NS      | 6 (10%)             |
| q+                     | 1 (3%)                          | 2 (7%)                        |         | 3 (5%)              |
| Polysomy               | 16 (59%)                        | 14 (45%)                      |         | 30 (52%)            |
| Chromosome 8           |                                 |                               |         |                     |
| Normal                 | 3 (11%)                         | 7 (23%)                       |         | 10 (17%)            |
| del(8p)                | 5 (19%)                         | 4 (13%)                       |         | 9 (15%)             |
| q+                     | 2 (7%)                          | 3 (9%)                        | NS      | 5 (9%)              |
| Del(8p)/8q+            | 12 (44%)                        | 8 (26%)                       |         | 20 (35%)            |
| Polysomy               | 5 (19%)                         | 9 (29%)                       |         | 14 (24%)            |
| Chromosome 13          |                                 |                               |         |                     |
| Normal                 | 7 (26%)                         | 13 (42%)                      | NS      | 20 (35%)            |
| Polysomy               | 20 (74%)                        | 18 (58%)                      |         | 38 (65%)            |
| Chromosome 14          |                                 |                               |         |                     |
| Normal                 | 15 (55%)                        | 19 (61%)                      |         | 34 (59%)            |
| del(14q)               | 4 (15%)                         | 1 (3%)                        | NS      | 5 (9%)              |
| Polysomy               | 8 (30%)                         | 11 (36%)                      |         | 19 (32%)            |
| Chromosome 17          |                                 |                               |         |                     |
| Normal                 | 5 (19%)                         | 20 (65%)                      |         | 25 (43%)            |
| del(17p)               | 20 (70%)                        | 6 (19%)                       | p<.001  | 26 (45%)            |
| Polysomy               | 2 (7%)                          | 5 (16%)                       |         | 7 (12%)             |
| Del(17p11.2)           | 18 (67%)                        | 3 (10%)                       | p<.001  | 21 (36%)            |
| Chromosome 18          |                                 |                               |         |                     |
| Normal                 | 13 (48%)                        | 17 (55%)                      |         | 30 (52%)            |
| del(18q)               | 14 (52%)                        | 10 (32%)                      | NS      | 29 (50%)            |
| Polysomy               | 0 (0%)                          | 4 (13%)                       |         | 4 (7%)              |
| Chromosome 20          |                                 |                               |         |                     |
| Normal                 | 5 (19%)                         | 12 (39%)                      |         | 17 (27%)            |
| 20q+                   | 17 (63%)                        | 12 (39%)                      | NS      | 29 (50%)            |
| Polysomy               | 5 (19%)                         | 7 (22%)                       |         | 12 (21%)            |
| Chromosome 22          |                                 |                               |         |                     |
| Normal                 | 15 (56%)                        | 23 (74%)                      |         | 38 (66%)            |
| del(22q)               | 6 (22%)                         | 0 (0%)                        | p = 0.02| 6 (10%)             |
| Polysomy               | 6 (22%)                         | 8 (26%)                       |         | 14 (24%)            |

Results expressed as number of cases and percentage of cases between brackets; NS: statistically not significant (p > .05).
doi:10.1371/journal.pone.0042683.t002

Validation of the clinical impact of del(17p11.2) and del(22q) in an independent series of patients

In order to confirm the prognostic impact of the two chromosomal abnormalities described above, we investigated their prognostic impact in an independent series of colorectal cancer patients from the public GEO database (n = 119). Noteworthy, also in this new series, patients whose tumors harboured pericentromeric breakpoints at 17p in the 17p11.2 chromosomal...
region (from 15 to 25 megabases from p-ter) were found to have an inferior clinical outcome than those harbouring del(17p13) alone (p = .02 and p = .04, respectively). The prognostic impact of del(17p11.2) was even stronger (p = .01) when all other tumors which showed pericentromeric deletions, including those with breakpoints in the q-arm close to the centromere (from 15 to 27.5 Mb from p-ter), were considered (Figure S1).

These results support the observations of our dataset and confirm the prognostic impact of del(17p11.2). However, the prognostic impact of del(22q) could not be confirmed (p > .05) in this new independent sCRC series of patients.

Discussion

sCRC patients who do not show or develop distant metastasis are often cured by surgical resection of the primary tumor with optional administration of adjuvant therapy. However, when metastasis to the liver and other organs occur, the chances of cure are dramatically reduced. Despite the fact that the understanding of the genetic mechanisms underlying the early stages of both familial [16] and sporadic CRC has significantly advanced in recent years [17], the genetic mechanisms responsible for progression of sCRC to a metastatic phenotype still remain poorly understood. In this study, we investigated the pattern of numerical chromosomal alterations of primary tumors from metastatic sCRC that exhibited synchronous liver metastases versus non-metastatic sCRC. In order to avoid false-negative non-metastatic cases, in this later group only sCRC with a relative long follow up (median follow-up of 99 months) were selected for the non-metastatic tumor group. Similarly, only liver metastatic cases who had undergone complete resection of both their primary and metastatic tumor, were included in the metastatic patient group.

iFISH probes targeting those chromosomal regions more frequently altered in sCRC [6] were specifically applied to the cytogenetic characterization of both patient groups and a new probe for the definition of del(17p) associated with breakpoints at chromosome 17p11.2, was also systematically used. In line with previous observations which show that liver metastatic and non-metastatic sCRC share multiple chromosomal alterations (e.g.,...
gains of chromosomes 7, 8q, 13q and 20q and losses of the 1p, 8p, 14q, 17p, 18q and 22q chromosomes) [7,18–20], here we also found a similar distribution between liver metastatic and non-metastatic tumors for most chromosomal alterations identified. In contrast, del(22q) and del(17p) (particularly when associated with breakpoints at chromosome 17p11.2), were significantly more prevalent or even restricted, to liver metastatic tumors. These later findings support a potential role for both del(17p11.2) and del(22q) in the metastatic process of sCRC to the liver.

Previous reports based on cytogenetic analyses of metastatic disease from colorectal tumors indicated that chromosome 17p is frequently lost in sCRC [21,22]. In line with other studies and using similar methodological approaches, our results showed the presence of del(17p11.3) in almost half of the sCRC cases studied.

### Table 3. List of genes encoded at chromosomal regions identified as being deleted by iFISH probes directed against the 17p11.2 (20156497 bp to 22975771 bp), 17p13.1 (7449445 bp to 7594642 bp) and 22q11.2 (21852397 bp to 21984023 bp) chromosomal regions: gene name, cell localization and function.

| Coded name | Gene | Cellular localization | Function |
|------------|------|-----------------------|----------|
| **17p11.2** | | | |
| C17orf103 | Chromosome 17 open reading frame 103 | Unknown | Unknown |
| C17orf51 | Chromosome 17 open reading frame 51 | Unknown | Unknown |
| CCDC144C | Coiled-coil domain containing 144C | Unknown | Unknown |
| CCDC144NL | Coiled-coil domain containing 144 family, N-terminal like | Unknown | Unknown |
| CDRT15L | CMT1A duplicated region transcript 15-like 2 | Unknown | Unknown |
| DHR57B | Dehydrogenase/reductase (SDR family) member 7B | Unknown | Metabolism |
| FAM160B | Family with sequence similarity 106, member B | Unknown | Unknown |
| FAM2L7 | Family with sequence similarity 27-like | Unknown | Unknown |
| KCNJ12 | Potassium inwardly-rectifying channel, subfamily J, member 12 | Membrane | Transport |
| LGALS9B | Lectin, galactoside-binding, soluble, 9B | Cytoplasm | Cell-cell adhesion |
| MAP2K3 | Mitogen-activated protein kinase kinase 3 | Cytoplasm | Cell death |
| MTRNR2L1 | MT-RNR2-like 1 | Unknown | Unknown |
| SPECC1 | Sperm antigen with calponin homology and coiled-coil domains 1 | Nuclear | Unknown |
| TMEM11 | Transmembrane protein 11 | Membrane | Transport |
| USP22 | Ubiquitin specific peptidase 22 | Nuclear | Cell cycle |
| **17p13.1** | | | |
| ATP1B2 | ATPase, Na+/K+ transporting, beta 2 polypeptide | Membrane | Metabolism |
| CD68 | CD68 molecule | Membrane | Metabolism |
| EIF4A1 | eukaryotic translation initiation factor 4A1 | Cytoplasm | Metabolism |
| FXR2 | fragile X mental retardation, autosomal homolog 2 | Cytoplasm | Metabolism |
| MPDU1 | mannose-P-dolichol utilization defect 1 | Cytoplasm | Metabolism |
| SAT2 | spermidine/spermine N1-acetyltransferase family member 2 | Membrane | Metabolism |
| SENP3 | SUMO1/sentrin/SMT3 specific peptidase 3 | Nuclear | Metabolism |
| SHBG | sex hormone-binding globulin | Extracellular | Cell death |
| SNORA67 | small nucleolar RNA, H/ACA box 67 | Unknown | Unknown |
| SNORD10 | small nucleolar RNA, C/D box 10 | Unknown | Unknown |
| SOX15 | SRY (sex determining region Y)-box 15 | Nuclear | Cell differentiation |
| TNFSF12 | tumor necrosis factor (ligand) superfamily, member 12 | Extracellular | Cell death |
| TNFSF13 | tumor necrosis factor (ligand) superfamily, member 13 | Extracellular | Cell death |
| TP53 | tumor protein p53 | Nuclear | Apoptosis |
| WRAP53 | WD repeat containing, antisense to TP53 | Nuclear | Telomerase activity |
| **22q11.2** | | | |
| PHKAP2 | Phosphatidylinositol 4-kinase, catalytic, alpha pseudogene 2 | Unknown | Metabolism |
| RIMBP3 | RIMS binding protein 3 | Nuclear | Unknown |
| SCARNA17 | Small Cajal body-specific RNA 17 | Unknown | Unknown |
| SCARNA18 | Small Cajal body-specific RNA 18 | Unknown | Unknown |
| UBE2L3 | Ubiquitin-conjugating enzyme E2L 3 | Cytoplasm | Metabolism |
| YDJC | YdjC homolog (bacterial) | Unknown | Metabolism |

Genes which have been associated with cancer are shown in bold.

doi:10.1371/journal.pone.0042683.t003
The frequency of del(17p13) was also significantly higher in liver metastatic than non-metastatic cases, as has been suggested by other groups [25–27]. It was noted that among cases with del(17p13), occurrence of a breakpoint at chromosome 17p11.2 was mostly restricted to metastatic sCRC. Coinciding with these observations, several authors have previously found that losses of chromosome 17p in metastatic CRC samples cover larger regions than in primary tumors, suggesting that unknown suppressor genes, other than the TP53 gene, could be involved in the newly deleted 17p sequences [28]. If this is confirmed, then these differences could explain why cases with del(17p) in the absence of TP53 mutations, also occur in advanced sCRC. Moreover, it provides evidence for the potential existence of new additional tumor suppressor genes (and potentially also oncogenes) coded in the centromeric portion of chromosome 17p, proximal to TP53. In this regard, it should be noted that several cancer associated genes (e.g.: KCNJ12, MAP2K3, and USP22) are coded in this chromosomal region, the first gene systematically deleted at this breakpoint region being a gene of unknown function (FAM27L). Interestingly, genetic polymorphisms involving this chromosomal region including the FAM27L gene, have been recently associated with an increased risk for chronic myeloid leukemia [29]. Further studies, in which mutations of this gene and deletions at chromosome 17p11.2 are searched for, may indicate their potential role in sCRC liver metastasis. Among other genes the MAP2K3 gene is also coded in chromosome 17 region found to be commonly deleted in metastatic sCRC. MAP2K3 is a strong promoter of tumor invasion, progression and short survival in several human cancers [30] and previous studies have shown that decreased expression of MAP2K3 is associated with human breast infiltrating ductal carcinomas [31]; similarly, non-synonymous coding SNPs downregulating KCNJ12 expression have been related with rhabdomyosarcomas [32], supporting a potential role for both genes in liver metastatic sCRC. However, in this chromosomal region, also some oncogenes are coded such as the USP22 gene. Recent studies have shown that aberrant expression of USP22 is associated with liver metastasis and poor prognosis [33], due to the fact that this gene positively regulates cell cycle via both the BMI-1-mediated INK4a/ARF pathway and the Akt signaling pathway [34]. However, the activation and oncogenic role of USP22 in the progression of sCRC is potentially linked to genes encoded in other chromosomal regions such as the BMI-1 (10p13), CMYC (8q24) and CCND2 (12p13) genes [35].

In addition to del(17p11.2), in this study we also found an association between losses of chromosome 22q and disease outcome, in line with previous observations [26,36,37]. Previous studies based on CGH analysis [38] have shown an association between del(22q) and liver metastasis among sCRC patients; similarly, Yana et al [39] showed that del(22q) correlates with the Duke’s stage of the disease. Iino et al [26] have suggested that LOH at chromosomes 17p, 18q, and 22q, is associated with an increased metastatic potential of sCRC. In the latter study, LOH at chromosome 17p was also significantly associated with vascular invasion, whereas 18q and 22q LOH correlated more with lymphatic dissemination of the disease; importantly, only LOH of chromosome 22q showed a significant association with the presence of lymph node metastasis. Thus, it could be hypothesized that in sCRC, these three chromosomal losses may be specifically associated with the metastatic process. If this holds true, screening for genetic abnormalities of primary sCRC tumors could be useful for predicting the metastatic potential which exists at the time of diagnosis [40]. It should be emphasized that analysis of del(17p11.2) in paired primary tumors and liver metastases from sCRC patients showed either presence or absence of these chromosomal changes in both (paired) tumor samples in all but two cases; in these later two cases, del(17p11.2) was only detected by SNP-arrays in the liver metastatic sample. Multivariate analysis of prognostic factors for OS, showed the independent prognostic value of the two chromosomal abnormalities, del(17p) with a breakpoint at 17p11.2 and del(22q);
consequently, coexistence of both chromosomal alterations was associated with a significantly reduced OS vs. cases which showed neither of these alterations (OS at 5 years of 0% versus 93%, respectively). Despite the fact that an association has been reported between different chromosomal abnormalities and the prognosis of sCRC [13], to the best of our knowledge there is the first report in which the independent prognostic value of del(17p) with a breakpoint at 17p11.2 and of del(22q) is described. Preliminary results using genome-wide array analyses have shown an association between specific genetic alterations present in primary sCRC tumors and patient survival [10,18,22]. Poulogiannis et al (using a DNA microarray platform covering the entire genome at an average of 1 Mb of resolution) identified DNA copy number losses at 18q12.2 to be an independent prognostic marker [10]. In the current study, we have re-analyzed this dataset and confirmed the prognostic value of del(17p) including that of del(17p) with a breakpoint at 17p11.2; in contrast, the clinical impact of del(22q) could not be validated in this series. Although the precise clinical value of del(22q) should be investigated further, validation of our data concerning the prognostic impact of the 17p11.2 breakpoint in an independent dataset (in spite of the substantial differences in the technologies applied in both studies) strengthens the evidence for the clinical relevance of chromosome 17p deletions encompassing genomic regions beyond the TP53 locus, and points to the potential role of other candidate genes coded at chromosome 17p centromerically to TP53. As discussed above, such genes include the MAP2K3, KCNJ12 and USP22 genes [30–35]. Interestingly, when we searched for direct interactions among the deleted genes and other cancer-associated genes, 30 genes deleted in cases with del(17p), and another 6 genes deleted in cases with del(22q), emerged as directly related to signaling pathways involved in cell growth and proliferation (e.g., EGFR and CDK1A) as well as in cell death (e.g., BAX and BCL2). These findings suggest a potential role for the combined deletion of these genes in conferring poor-prognosis to sCRC with coexisting del(17p) and del(22q), possibly due to increased cell proliferation and survival and diminished DNA repair.

In summary, in the present study we show that the presence of del(17p) with a breakpoint at 17p11.2 is an independent adverse prognostic factor for OS of sCRC. When combined with del(22q11.2) it allowed the identification of three groups of sCRC patients with significantly different outcome, which could be predicted at diagnosis. Further prospective studies are required in larger series of sCRC patients to confirm the prognostic value of the combined assessment of del(17p) and del(22q) in primary tumor samples at diagnosis and the precise role of the deleted genes.

Supporting Information

Figure S1 Validation of the impact of chromosome 17 status on overall survival in an independent series of sCRC patients from the GEO database (n = 109); panel A, del(17p13); panels B and C, del(17p) harbouring pericentromeric breakpoints at chromosome 17p and del(17p) harboring a pericentromeric breakpoint at both chromosomes 17p and 17q, respectively. (TIF)

Author Contributions

Conceived and designed the experiments: AO JMS. Performed the experiments: MGG LMB MLG MMA OB EF. Analyzed the data: MGG CM CF JR MF JMS CT. Contributed reagents/materials/analysis tools: MGG CM CF JR MF JMS. Wrote the paper: MGG LMB CM CF MLG MMA OB EF MF JR AO JMS.

References

1. Sartore-Bianchi A, Moroni M, Veronesi S, Carnaghi C, Bajetta E, et al. (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25: 3238–3245.
2. Sayago JM, Abad MdL, Melchor HB, Gutierrez ML, Gonzalez-Gonzalez M, et al. (2010) Intratumoral cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. J Pathol 221: 308–319.
3. Arnold CN, Geel A, Blum HE, Boland CR (2005) Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer 104: 2055–2074.
4. Ashktorab H, Schaffer AA, Darmenpouru M, Smoot DT, Lee E, et al. (2010) Distinct genetic alterations in colorectal cancer. PLoS One 5: e8879.
5. Hu XT, Chen W, Wang D, Shi QL, Zhang FH, et al. (2008) The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer. Oncol Rep 19: 441–446.
6. Sayago JM, Fontanillo C, Abad MdL, Gonzalez-Gonzalez M, Sarastequ ME, et al. (2010) Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays. PLoS One 5: e13752.
7. Camps J, Grade M, Nguyen QT, Hermann P, Becker S, et al. (2008) Chromosomal breakpoints in primary colon cancer cluster at sites of structural variants in the genome. Cancer Res 68: 1284–1295.
8. World Health Organization. WHO (1981) International Histological Classification of Tumours V-G, 1967–1981; 2nd edn, Berlin: Springer-Verlag, 1988–1992.
9. Muñoz-Belvis I, Fontanillo C, Gonzalez-Gonzalez M, Garcia E, Iglesias M, et al. (2012) Unique genetic profile of sporadic colorectal cancer liver metastasis versus primary tumors as defined by high-density single-nucleotide polymorphism arrays. Mod Pathol.
10. Poulogiannis G, Brustner K, Hammoud RA, Luo F, Leung SY, et al. (2010) Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol 220: 338–347.
11. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevilla V, Llobram-Bosch A, et al. (2012) 1q gain and CD102 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 31: 1287–1298.
12. Re M, Maglino L, Tarchini P, Mallardi V, Rubini C, et al. (2011) p53 and BCL-2 over-expression inversely correlates with histological differentiation in occupational esophageal intestinal-type sinonasal adenocarcinoma. Int J Immunopathol Pharmacol 24: 603–609.

13. Aghaur U, Hawkes E, Cunningham D. (2010) Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 9: 274–281.
14. Yashiro M, Harzavka K, Boland CR. (2010) Mutations in TGFBeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability. BMC Cancer 10: 303.
15. Seiran S, Forouhi G, Boers JE, Mocan T, Seiran A, et al. (2011) The prognostic role of apoptosis mediators in rectal adenocarcinoma. Hepatogastroenterology 58: 1490–1494.
16. Syngal S, Fox EA, Li C, Dovidio M, Eng C, et al. (1999) Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA 282: 247–253.
17. Maltzman T, Knoll K, Martinez SE, Byers T, Stevens BR, et al. (2001) K-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology 121: 302–309.
18. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, et al. (2009) Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Nad Acad Sci U S A 106: 7131–7136.
19. Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkert PT, et al. (2008) Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pival tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis 29: 434–439.
20. Popat S, Zhao D, Chen Z, Pan H, Shao Y, et al. (2007) Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 289 patients. Anticancer Res 27: 627–633.
21. Khine K, Smith DR, Goh HS (1994) High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer 73: 28–35.
22. Diep CB, Thoerstens L, Meling GI, Skovlund E, Rognum TO, et al. (2003) Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol 21: 820–829.
23. Garcia J, Duran A, Tabernero MD, Garcia Plaza A, Flores Corral T, et al. (2012) 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 31: 1287–1298.
24. Re M, Maglino L, Tarchini P, Mallardi V, Rubini C, et al. (2011) p53 and BCL-2 over-expression inversely correlates with histological differentiation in occupational esophageal intestinal-type sinonasal adenocarcinoma. Int J Immunopathol Pharmacol 24: 603–609.
24. Risio M, Casorzo L, Chiecchio L, De Rosa G, Rossini FP (2003) Deletions of 17p are associated with transition from early to advanced colorectal cancer. Cancer Genet Cytogenet 147: 44–49.

25. Losi L, Luppi G, Benhattar J (2004) Assessment of K-ras, Smad4 and p53 gene alterations in colorectal metastases and their role in the metastatic process. Oncol Rep 12: 1221–1225.

26. Ino H, Fukayama M, Maeda Y, Koike M, Mori T, et al. (1994) Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 73: 1324–1331.

27. Chang SC, Lin JK, Lin TC, Liang WY (2005) Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody, is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 26: 65–75.

28. Paredes-Zaglul A, Kang JJ, Essig YP, Mao W, Irby R, et al. (1998) Analysis of colorectal cancer by comparative genomic hybridization: evidence for induction of the metastatic phenotype by loss of tumor suppressor genes. Clin Cancer Res 4: 479–486.

29. Kim DH, Lee ST, Won HH, Kim S, Kim MJ, et al. (2011) A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood 117: 6906–6911.

30. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, et al. (2010) Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem 285: 14160–14169.

31. Jia M, Souchelnytskyi N, Hellman U, O’Hare M, Jat PS, et al. (2010) Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is downregulated in human breast cancer. Proteomics Clin Appl 4: 816–828.

32. Sher RB, Cox GA, Mills KD, Sundberg JP (2011) Rhabdomyosarcomas in aging A/J mice. PLoS One 6: e23498.

33. Liu YL, Yang YM, Xu H, Dong XS (2011) Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol 103: 263–269.

34. Liu YL, Jiang SX, Yang YM, Xu H, Liu JL, et al. (2012) USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys 62: 229–233.

35. Liu YL, Yang YM, Xu H, Dong XS (2010) Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol 25: 1800–1805.

36. Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF, et al. (1999) Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer. Gastroenterology 117: 831–837.

37. Castells A, Gusella JF, Ramesh V, Rustgi AK (2000) A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 60: 2036–2039.

38. Al-Mulla F, Keith WN, Pickford IR, Geising JJ, Birnie GD (1999) Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases. Genes Chromosomes Cancer 24: 306–314.

39. Yana I, Kurahashi H, Nakamori S, Kameyama M, Nakamura T, et al. (1995) Frequent loss of heterozygosity at telomeric loci on 22q in sporadic colorectal cancers. Int J Cancer 60: 174–177.

40. Ghadimi BM, Grade M, Monkmeyer C, Kulle B, Gaedcke J, et al. (2006) Distinct chromosomal profiles in metastasizing and non-metastasizing colorectal carcinomas. Cell Oncol 28: 273–281.